The Role of TP53 and MDM2 Polymorphisms in TP53 Mutagenesis and Risk of Non-melanoma Skin Cancer

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2010 Dec 3

PMID 21123835

Citations 13

Authors

Lindsay M Almquist

Margaret R Karagas

Brock C Christensen

Marleen M Welsh

Ann E Perry

Craig A Storm

Heather H Nelson

Affiliations

Soon will be listed here.

Abstract

P53 is a key regulatory molecule in the cellular response to ultraviolet radiation, and TP53 mutation is the most common alteration in non-melanoma skin cancer. The MDM2 oncogene negatively regulates p53 protein levels, and both genes have functional polymorphisms that may modify skin cancer risk. Furthermore, prior research suggests that TP53 mutations preferentially occur on the arginine allele to selectively inactivate the p63 pathway. We tested these hypotheses of susceptibility and preferential mutation in non-melanoma skin cancer. The TP53 Arg72Pro and MDM2 309 polymorphisms were genotyped in a population-based case-control study of non-melanoma skin cancer, and TP53 alteration (mutation and immunohistochemistry staining) was evaluated in case tumors. In 902 cases of basal cell carcinoma (BCC), 676 cases of squamous cell carcinoma (SCC) and 812 controls, no association was found between the TP53 polymorphism and risk of non-melanoma skin cancer [odds ratio (OR)(BCC) 0.98, 95% confidence interval (CI) 0.80-1.20; OR(SCC) 0.93, 95% CI 0.75-1.16]. However, carriers of the MDM2 SNP309 G allele did have an elevated risk of non-melanoma skin cancer (OR(BCC) 1.15, 95% CI 0.93-1.42; OR(SCC) 1.29, 95% CI 1.02-1.63). We observed an association between TP53 alterations in the tumors and constitutive TP53 genotype (P < 0.01), with alterations preferentially occurring on the proline allele. Collectively, these data highlight the significant effects of genotype on gene-specific mutation events in carcinogenesis.

Citing Articles

Advances in cutaneous squamous cell carcinoma.

Winge M, Kellman L, Guo K, Tang J, Swetter S, Aasi S Nat Rev Cancer. 2023; 23(7):430-449.

PMID: 37286893 DOI: 10.1038/s41568-023-00583-5.

The relationship between single nucleotide polymorphisms and skin cancer susceptibility: A systematic review and network meta-analysis.

Zhang L, Pozsgai E, Song Y, Macharia J, Alfatafta H, Zheng J Front Oncol. 2023; 13:1094309.

PMID: 36874118 PMC: 9975575. DOI: 10.3389/fonc.2023.1094309.

Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas.

Campos M, Macedo S, Fernandes M, Pestana A, Pardal J, Batista R Genes (Basel). 2020; 11(7).

PMID: 32640663 PMC: 7397334. DOI: 10.3390/genes11070751.

Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population.

Akhter N, Dar S, Chattopadhyay S, Haque S, Anwer R, Wahid M Curr Genomics. 2018; 19(5):395-410.

PMID: 30065615 PMC: 6030857. DOI: 10.2174/1389202919666171205104137.

TP53 Gene Polymorphisms and Occupational Skin Cancer Risks for Workers of Glass Fiber Manufacture.

Mukhammadiyeva G, Karimov D, Bakirov A, Karimova L Iran J Public Health. 2017; 46(11):1495-1501.

PMID: 29167767 PMC: 5696688.

References

King K, Weinberg W . p63: defining roles in morphogenesis, homeostasis, and neoplasia of the epidermis. Mol Carcinog. 2007; 46(8):716-24. DOI: 10.1002/mc.20337. View

Nan H, Qureshi A, Hunter D, Han J . A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control. 2008; 20(2):171-9. PMC: 2631619. DOI: 10.1007/s10552-008-9231-9. View

Karagas M, Greenberg E, Spencer S, Stukel T, Mott L . Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer. 1999; 81(4):555-9. DOI: 10.1002/(sici)1097-0215(19990517)81:4<555::aid-ijc9>3.0.co;2-r. View

Toguchida J, Yamaguchi T, Dayton S, Beauchamp R, Herrera G, Ishizaki K . Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med. 1992; 326(20):1301-8. DOI: 10.1056/NEJM199205143262001. View

Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L . Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2005; 43(6):531-3. PMC: 1904480. DOI: 10.1136/jmg.2005.037952. View

Marin M, Jost C, Brooks L, Irwin M, ONions J, Tidy J . A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000; 25(1):47-54. DOI: 10.1038/75586. View

Dumont P, Leu J, Della Pietra 3rd A, George D, Murphy M . The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003; 33(3):357-65. DOI: 10.1038/ng1093. View

Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N . A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602. DOI: 10.1016/j.cell.2004.11.022. View

Kelsey K, Hirao T, Hirao S, Devi-Ashok T, Nelson H, Andrew A . TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. Int J Cancer. 2005; 117(3):370-5. DOI: 10.1002/ijc.21195. View

10.

Bendesky A, Rosales A, Salazar A, Sordo M, Peniche J, Ostrosky-Wegman P . p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. Mutat Res. 2007; 619(1-2):38-44. DOI: 10.1016/j.mrfmmm.2007.01.001. View

11.

Mills A, Zheng B, Wang X, Vogel H, Roop D, Bradley A . p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999; 398(6729):708-13. DOI: 10.1038/19531. View

12.

Ara S, Lee P, Hansen M, Saya H . Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990; 18(16):4961. PMC: 332028. DOI: 10.1093/nar/18.16.4961. View

13.

Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G . Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999; 19(2):1092-100. PMC: 116039. DOI: 10.1128/MCB.19.2.1092. View

14.

Harris S, Gil G, Robins H, Hu W, Hirshfield K, Bond E . Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci U S A. 2005; 102(45):16297-302. PMC: 1283473. DOI: 10.1073/pnas.0508390102. View

15.

Chen Y, Xu L, Guo Y, Su H, Hsueh Y, Smith T . Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003; 38(1):201-11. DOI: 10.1081/ese-120016889. View

16.

McGregor J, Harwood C, Brooks L, Fisher S, Kelly D, ONions J . Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol. 2002; 119(1):84-90. DOI: 10.1046/j.1523-1747.2002.01655.x. View

17.

Nelson H, Wilkojmen M, Marsit C, Kelsey K . TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis. 2005; 26(10):1770-3. DOI: 10.1093/carcin/bgi125. View

18.

Wilkening S, Lorenzo Bermejo J, Hemminki K . MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007; 28(11):2262-7. DOI: 10.1093/carcin/bgm191. View

19.

Han J, Cox D, Colditz G, Hunter D . The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol Carcinog. 2006; 45(9):694-700. DOI: 10.1002/mc.20190. View

20.

Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson R . p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999; 398(6729):714-8. DOI: 10.1038/19539. View